Provera, tablets 500 mg 30 pcs

Pharmacodynamics

Gestagen. Does not have androgenic and estrogenic activity. Inhibits the secretion of gonadotropic hormones (especially LH). In small doses it suppresses ovulation. It has an inhibitory effect on changes necessary for the preparation of the endometrium for implantation of the fertilized egg and increases the viscosity of cervical mucus.

In higher doses it has antitumor effects in hormone-sensitive malignancies. This effect appears to be due to an effect on steroid hormone receptors and on the pituitary-gonadal system.

Pharmacokinetics

The binding to plasma proteins is 90-95%. It penetrates through the BBB and is excreted with breast milk. It is metabolized in the liver.

T_1/2 is about 30 hours. It is excreted with the bile and urine as metabolites and unchanged.

Indications

For use in gynecology:

For use in oncology:

Active ingredient

Composition

1 tablet contains:

Active ingredients:

Medroxyprogesterone (in acetate form) 500 mg.

Auxiliary substances:

Corn starch;

Magnesium stearate;

MC;

Gelatin;

polyethylene glycol 400;

sodium salt of starch;

docusate sodium (85%) with sodium benzoate (15%).

There are 10 tablets in the blister.

There are 3 blisters in the package.

How to take, the dosage

Set individually, depending on the indication, stage of the disease, the therapy regimen.

Interaction

Concomitant use with aminoglutethimide may decrease the plasma concentration of medroxyprogesterone.

Concomitant use with drugs that cause induction of microsomal liver enzymes may reduce the contraceptive effect of medroxyprogesterone during parenteral administration.

Carbamazepine, griseofulvin, phenobarbital, phenytoin, rifampicin may increase the clearance of gestagens (progestagens).

Gestagens (progestagens) can change the effectiveness of hypoglycemic drugs.

Gestagens (progestagens) may inhibit the metabolism of cyclosporine, resulting in increased plasma concentrations and an increased risk of toxicity.

Special Instructions

The dosage form used must be closely matched to the indications for use.

Medroxyprogesterone should be used with particular caution in patients with thrombophlebitis, thromboembolic complications, severe liver dysfunction, and hypercalcemia.

Before using medroxyprogesterone for the treatment of gynecological diseases and contraception, the patient must rule out the presence of a tumor of the genitals or mammary glands.

If a pathohistological examination of certain organs and tissues is performed, the histologist should be warned about previous treatment with progestagens. Against the background of medroxyprogesterone use the results of the following studies may change: determination of gonadotropin levels; determination of progesterone, cortisol, testosterone (in men), estrogen (in women) levels in blood plasma; determination of pregnandiol levels in urine; conducting a sugar load test; conducting a metapyrone test.

Contraindications

Side effects

CNS disorders: headache, irritability, sleep disorders, drowsiness, fatigue, depression, dizziness.

Digestive system disorders: nausea.

Allergic reactions: urticaria, itching, rash, anaphylactoid reactions.

Hematopoietic system disorders: thromboembolic disorders.

Endocrine system disorders: mammary gland hypersensitivity, galactorrhea, erosion and changes in cervical secretion. When used at a dose of 500 mg/day or more, acne, hirsutism, weight gain, “moon-shaped” face are possible.

Others: hyperthermia.

Pregnancy use

It is contraindicated in pregnancy.

It does not affect lactation. It is excreted with breast milk in small amounts, and negative effects on the development of children receiving this milk are not observed.